CO44195
Trial Overview
Official Title
A Phase II, Single-Arm Study of Giredestrant in Patients with Grade 1 Endometrial Cancer
Study Purpose
To assess the efficacy, safety, and pharmacokinetics of giredestrant in participants with Grade 1 endometrioid endometrial carcinoma.
Diagnosis
Grade 1 endometrioid endometrial carcinoma.Eligibility
Newly diagnosed endometrial cancer with no prior treatment.
Intervention
Giradestrant daily oral medication.
For more information
visit Clinicaltrials.gov
Key Participation Requirements
Trial Location(s)
Gender
Female
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
CO44195